Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
Disc Medicine (IRON) Stock Price & Analysis
206 Followers
IRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.60 - $77.60
Previous Close$44.43
Volume244.23K
Average Volume (3M)417.81K
Market Cap
$1.32B
Enterprise Value$959.76M
Total Cash (Recent Filing)$360.38M
Total Debt (Recent Filing)$2.10M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 09, 2024EPS Estimate
-$1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding24,721,666
10 Day Avg. Volume576,341
30 Day Avg. Volume417,806
Standard Deviation0.22
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.58
Forecast
1Y Price Target
$64.33Price Target Upside37.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Disc Medicine News
PremiumCompany Announcements
Disc Medicine Unveils Promising Clinical Trial Results at EHA CongressBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsIRON presented updated data from a Phase 1b trial of DISC-0974 in myelofibrosis patients with anemia, showing encouraging reductions in hepcidin and increases in serum iron levels.
Financial PerformanceThe company also completed a $178mn secondary offering, bringing their pro-forma cash to $520mn with an operational runway into 2027.
Hematology PipelineAnalysts view the updates on DISC-0974 and DISC-3405 as highly encouraging and clear positives for IRON shares, continuing to build the story across multiple differentiated mechanisms, indications, and opportunities.
Bears Say
Clinical Trial ResultsAn outsized placebo response in light tolerance secondary endpoints introduced some uncertainty regarding the clinical regulatory path forward.
Efficacy ConcernsThe placebo arm in the study meaningfully outperformed expectations, raising questions about the efficacy of the treatment.
Financial OutlookThe price target for IRON has been adjusted to $65 from the previous $77.
---
Ownership Overview
72.86% Insiders
9.68% Mutual Funds
6.76% Other Institutional Investors
10.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $25.60 and its highest was $77.60 in the past 12 months.
What is Disc Medicine’s market cap?
Currently, no data Available
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Aug 09, 2024 which is in 34 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on May 09, 2024. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$1.008 by -$0.082.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -$1.1.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 29,665,667 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.09 in its last earnings report, missing expectations of -$1.008. Following the earnings report the stock price went up 4.874%.
Which hedge fund is a major shareholder of Disc Medicine?
Among the largest hedge funds holding Disc Medicine’s share is Perceptive Advisors LLC. It holds Disc Medicine’s shares valued at 59M.
---
Disc Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.33 (37.99% Upside)
$64.33 (37.99% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 118.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $14.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.63%
12-Months-Change
Fundamentals
Return on Equity
-28.23%
Trailing 12-Months
Asset Growth
45.29%
Trailing 12-Months
Company Description
Disc Medicine
FS Development Corp is a blank check company.
---
IRON Stock 12 Month Forecast
Average Price Target
$64.33
▲(37.99% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering IRON
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
+0.29%
reiterated a buy rating 22 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +0.29% per trade.
---